Pathos AI raises $237M Series E led by Bristol Myers Squibb
The AI drug developer is now valued at about $3 billion, and BMS also gets access to its Foundry platform for neuroscience programs.
The AI drug developer is now valued at about $3 billion, and BMS also gets access to its Foundry platform for neuroscience programs.